Clinical scope expansion Sarkis Clinical Trials specializes in Phase I-IV studies for CNS/Psychiatry and related disorders, with pediatric and adult trials. This indicates potential for expanded CRO services in neuropsychiatric research and complementary CNS trial capabilities.

Sleep and neuroscience assets Access to a sleep laboratory and EEG equipment opens opportunities to partner on CNS trials requiring advanced neurological endpoints, sleep disorder studies, or EEG-driven safety/efficacy assessments.

Integrated care ecosystem Sarkis has a sister company offering TMS, counseling, and other therapies, presenting a cross-sell path to comprehensive trial recruitment, post-trial care, and integrated mental health treatment services.

Moderate scale growth With 11-50 employees and annual revenue in the mid single to low double digits, Sarkis presents a nimble, cost-efficient partner for focused clinical programs, potentially appealing to sponsors looking for tight project management and quicker cycles.

Strategic positioning for sponsors Targeting CNS, ADHD, depression, anxiety, bipolar, autism, and migraines positions Sarkis to align with neuroscience-focused sponsors and contract their early-phase to late-phase studies, especially those seeking psychiatric populations and pediatric inclusion.